ASO (Anti-sense Oligonucleotide)

TASO (TGF-β2 Targeting ASO)

TGF-β2 targeting ASO anti-cancer new drug used in combination with IL-2 (Interleukin-2)

Science & Innovation Features

18-mer phosphorothioate Anti-sense Oligonucleotide targeting human TGF-β2
Designed based on the correlation between TGF-β overexpression and tumor progression
Bind complementary to mRNA to inhibit TGF-β expression
Validated for efficacy and safety through phase 2 clinical trial

TASO

Weakening defensive mechanism of cancer cell by suppressing TGF-β2

IL-2

Strengthen T cell’s functions to attack cancer cell

Maintaining the efficacy while reducing IL-2 dosage

Suppression of tumor growth and increase of CD8 T cells in cancer tissue through inhibition of TGF-β2 in pancreatic cancer model

Scheme

Privacy Policy
Headquarter.#302, 194-41, Osong-saengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, 28610, Republic of Korea
R&D Center.#510 Signature Gwanggyo Knowledge Business Center 37, Poeun-daero 59beon-gil, Suji-gu, Yongin-si, Gyeonggi-do, 16864, Republic of Korea
- T.043-233-9373
- F.043-233-9374
- E.info@autotelic.co.kr